Drugs Containing Excipient (Inactive Ingredient) BUTYLATED HYDROXYTOLUENE

Branded drugs containing BUTYLATED HYDROXYTOLUENE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	ISENTRESS	raltegravir	0006-0227	BUTYLATED HYDROXYTOLUENE
Merck Sharp & Dohme Corp	FOSAMAX PLUS D	alendronate sodium and cholecalciferol	0006-0710	BUTYLATED HYDROXYTOLUENE
Allergan Inc	RHOFADE	oxymetazoline hydrochloride	0023-5300	BUTYLATED HYDROXYTOLUENE
Allergan Inc	CONDYLOX	podofilox	0023-6118	BUTYLATED HYDROXYTOLUENE
Allergan Inc	TAZORAC	tazarotene	0023-8335	BUTYLATED HYDROXYTOLUENE

Generic drugs containing BUTYLATED HYDROXYTOLUENE excipient

Company	Ingredient	NDC	Excipient
Merck Sharp & Dohme LLC	raltegravir	0006-0227	BUTYLATED HYDROXYTOLUENE
Merck Sharp & Dohme Corp	alendronate sodium and cholecalciferol	0006-0710	BUTYLATED HYDROXYTOLUENE
Allergan Inc	oxymetazoline hydrochloride	0023-5300	BUTYLATED HYDROXYTOLUENE
Allergan Inc	podofilox	0023-6118	BUTYLATED HYDROXYTOLUENE
Allergan Inc	tazarotene	0023-8335	BUTYLATED HYDROXYTOLUENE

Market Dynamics and Financial Trajectory for Butylated Hydroxy Toluene (BHT) in Pharmaceuticals

Last updated: March 18, 2026

What is the Role of BHT in Pharmaceutical Manufacturing?

Butylated Hydroxy Toluene (BHT) remains predominantly used as an antioxidant and preservative in pharmaceutical formulations. It prevents oxidation of active ingredients, extending shelf life and maintaining drug stability. Although its application in pharmaceuticals is limited compared to its extensive use in food and cosmetics industries, BHT's role as a stabilizer in oral solid dosage forms and topical products is recognized.

Market Size and Growth Trends

Global Market Valuation

The pharmaceutical excipient market was valued at approximately USD 4.2 billion in 2022. BHT accounts for a small, niche segment within this, estimated at less than 1%. The process of manufacturing BHT, primarily driven by chemical synthesis via alkylation of hydroxytoluene, restricts extensive pharmaceutical use. Estimated revenue from BHT sales in pharmaceuticals is below USD 50 million annually.

Growth Drivers

• Demand for Stabilizers: Trends favor non-volatile, cost-effective antioxidants for formulation stability.
• Regulatory Status: BHT's status as a Generally Recognized As Safe (GRAS) substance in food correlates with some pharmaceutical approvals, supporting incremental demand.
• R&D for Alternative Antioxidants: Development of natural antioxidants may limit long-term growth.

Market Constraints

• Toxicity and Regulatory Concerns: BHT's safety profile in high concentrations prompts stringent regulatory scrutiny. Some agencies, such as the European Food Safety Authority, have raised health concerns, restricting allowable levels.
• Alternative Excipients: Preferential shift toward natural antioxidants (e.g., vitamin E derivatives, plant extracts) reduces BHT demand.
• Limited Pharmaceutical Proprietary Use: Patent protections for BHT are largely expired, limiting exclusivity benefits.

Supply Chain and Manufacturing Dynamics

Major Producers

Top chemical companies like Eastman Chemical Company, LANXESS, and SI Group manufacture BHT, with global supply secured through large-scale synthesis facilities primarily in North America, Europe, and Asia.

Cost Structure

• Production cost per kilogram ranges from USD 5 to USD 8, influenced by raw material prices (e.g., phenol, toluene), energy costs, and environmental compliance.

Price Trends

• Wholesale prices vary between USD 10 to USD 20 per kilogram.
• Price fluctuations align with raw material prices and regulatory costs.

Regulatory Landscape

• BHT is approved in the U.S. by the FDA for food use, with no prohibition in pharmaceuticals.
• In the European Union, BHT faces restrictions for food additives but is permitted at low levels as a pharmaceutical excipient.
• Ongoing safety assessments influence allowable concentrations.

Competitive Position and Future Outlook

Competitive Factors

• Cost efficiency of production.
• Regulatory compliance and safety profile.
• Availability of alternative antioxidants.
• Customer preference for natural excipients.

Future Trajectory

• Market growth is projected to remain stable or decline marginally, with a compound annual growth rate (CAGR) of approximately 0.5% over the next five years.
• Transition toward natural antioxidants and regulatory tightening will constrain growth.
• Continued manufacturing for food and cosmetic markets sustains the supply of BHT, indirectly supporting pharmaceutical-grade supply.

Financial Implications for Stakeholders

Investment Risks

• Regulatory shifts can impact manufacturing and demand.
• R&D investments toward natural antioxidants could replace BHT in formulations.
• Volatility in raw material and energy prices affects costs.

Opportunities

• Process improvements reducing production costs.
• Expansion into niche pharmaceutical applications with higher purity standards.
• Collaborations with regulatory bodies to establish safe usage guidelines.

Key Takeaways

• The pharmaceutical excipient market for BHT is small, with limited growth prospects.
• Major suppliers have established manufacturing capacities, ensuring stable supply.
• Regulatory scrutiny and competition from natural antioxidants will constrain demand.
• Price stability is influenced by raw material costs and environmental compliance.
• Strategic opportunities exist in niche applications and process optimization.

FAQs

1. What is the primary pharmaceutical application of BHT?
   It functions as an antioxidant to stabilize drugs against oxidation, especially in oral solid dosage forms and topical products.

2. How does regulatory status affect BHT's market potential?
   Restrictions and safety assessments limit maximum permissible levels, discouraging extensive use and reducing market growth.

3. Are there natural alternatives to BHT in pharmaceuticals?
   Yes, antioxidants such as tocopherols (vitamin E derivatives) and plant extracts are increasingly used as natural preservatives.

4. What factors influence BHT prices in the pharmaceutical sector?
   Raw material costs, environmental regulations, and demand from food and cosmetic industries influence pricing.

5. Is BHT's use in pharma expanding or contracting?
   It is largely stable or declining due to safety concerns and the shift toward natural excipients.

---

References

[1] MarketsandMarkets (2022). Pharmaceutical excipient market report.
[2] European Food Safety Authority (2021). Safety assessment of BHT.
[3] Eastman Chemical Company (2023). BHT manufacturing and applications.
[4] FDA (2021). Food additives permitted for direct addition to food for human consumption.
[5] Lanxess (2022). Global BHT production capacity overview.